Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasm Metastasis 2Neoplasm, Residual 1

Interventions

pembrolizumab 34Specimen Handling 26Magnetic Resonance Spectroscopy 26Radiosurgery 25Biopsy 25Gemcitabine 22Nivolumab 21Paclitaxel 18Carboplatin 16Bevacizumab 15Trastuzumab 14Everolimus 12Radiotherapy 11Irinotecan 11trastuzumab deruxtecan 10atezolizumab 10Erlotinib Hydrochloride 10Docetaxel 10Cetuximab 10Capecitabine 10Albumin-Bound Paclitaxel 10130-nm albumin-bound paclitaxel 10Sorafenib 9Ipilimumab 9Cisplatin 9Taxes 8Standard of Care 8Oxaliplatin 8Drug Therapy 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Mercaptopurine × Tumor-Agnostic × Clear all
NCT05276284 2026-01-14

TEMPLE

Rigshospitalet, Denmark

Phase 1/2 Completed
18 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02067143 2021-09-08

LAL1913

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Completed
204 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡